Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate α-particle radioimmunotherapy
Authors:
- Jostein DahleJDJostein Dahle
- Jørgen BorrebækJBJørgen Borrebæk
- Katrine B. MelhusKMKatrine B. Melhus
- Øyvind S. BrulandØBØyvind S. Bruland
- Gro SalbergGSGro Salberg
- Dag Rune OlsenDODag Rune Olsen
- Roy H. LarsenRLRoy H. Larsen
- 1 February 2006
- journal article
- research article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 33 (2) , 271-279
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- 131I-Tositumomab Therapy as Initial Treatment for Follicular LymphomaNew England Journal of Medicine, 2005
- Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell LymphomaClinical Lymphoma, 2004
- What Is New in Lymphoma?CA: A Cancer Journal for Clinicians, 2004
- Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild ThrombocytopeniaCancer Biotherapy and Radiopharmaceuticals, 2004
- Evaluation of potential chelating agents for radiumApplied Radiation and Isotopes, 2002
- Tumor Therapy with Targeted Atomic NanogeneratorsScience, 2001
- Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate 211At-rituximab against non-Hodgkin's lymphoma cellsBritish Journal of Cancer, 2000
- Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experienceBlood, 2000
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- Treatment of Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993